Interleukin 4 News and Research

RSS

Food allergy sufferers offered hope of new treatment

In a joint UK and Italian study scientists say they have discovered a possible treatment for people who suffer from food allergies.

3 Jul 2007

Results of Tocilizumab study

Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

Genetic factors linked to adverse events related to smallpox vaccination

The study, published in the July 15th issue of The Journal of Infectious Diseases, now available online, may have implications for predicting adverse events from other live vaccines. .

17 Jun 2007

Impaired anti-inflammatory response plays role in pathology of type 2 diabetes

Type 2 diabetes is classified as a metabolic disorder, but a growing number of researchers are beginning to think of it also as a disease of the innate immune system. Inflammation, a key component of the early immune response, is chronically elevated in people with type 2 diabetes.

17 Jun 2007

New era of treatment for rheumatoid arthritis

Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition.

16 Jun 2007

New genetic risk factor for coeliac disease

An international research consortium investigating the genetic causes of intestinal inflammatory conditions has identified a new genetic risk factor for coeliac disease.

14 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Brain inflammation may actually be a friend for Alzheimer's patients

Inflammation in the brain may not be so bad after all when it comes to Alzheimer's disease.

3 Jun 2007

Blood test may help signal tumor's remission, return in throat cancer patients

A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research .

3 Jun 2007

Green tea may help prevent bone destruction in arthritis

In rheumatoid arthritis, a person's own immune system attacks the joints by activating the synovial tissue that lines the body's movable joints, causing inflammation, swelling, pain and eventually erosion of the bone and cartilage and deformation of the joint.

30 Apr 2007

Green tea may soothe pain of rheumatoid arthritis

According to the latest research a compound in green tea may provide therapeutic benefits to people with rheumatoid arthritis.

30 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007